Prevalence and Incidence of Migraine in Pediatric and Adolescent Populations: Insights from a Targeted Literature Review

Document Type

Presentation

Loading...

Media is loading
 

Publication Date

7-22-2025

Comments

Presentation: 20:43

Abstract

Migraine affects 7.7% to 9.1% of children globally and impairs quality of life. However, pediatric migraine remains underdiagnosed and undertreated, with few approved preventive treatments. Understanding the epidemiological burden is essential to support regulatory expansion and market access of new preventive therapies. This study aimed to synthesize the evidence on migraine prevalence and incidence in children and adolescents aged 6-17 years in the 30 regions including the United States (US), Canada, Brazil, and the 27 European Union (EU) member states. A targeted literature review (TLR) was conducted using PubMed to identify relevant studies. Data were extracted on country, age group, migraine definition, prevalence and incidence. Supplementary data were obtained from Vizhub, an online tool that models disease burden using data from the Global Burden of Disease Study 2021. A gap analysis was conducted to identify evidence limitations. Of the 30 migraine studies included in the TLR, 28 reported on prevalence and 2 on incidence. Data were available for 13 of the 30 regions including 10 of 27 EU countries. Prevalence ranged from 0.15%-21.4% in the EU, 4.7%-32.2% in Brazil, 0.7%-9.4% in Canada, and 6.1%-12.3% in the US. Vizhub reported prevalence for ages 5-19: 7.1%-15.5% across the EU, 11% in Canada, 11.2% in the US, and 16.7% in Brazil. Incidence from the TLR was available only for Finland and the US. Evidence gaps included few studies, lack of studies matching the age range of interest, missing methodological details and variability in diagnostic criteria. These gaps highlight the need for well-designed, region-specific epidemiological studies on pediatric populations aged 6-17, with age stratification, and complete reporting to inform regulatory and reimbursement strategies for preventive therapies.

Language

English

This document is currently not available here.

Submit Feedback on Presentation

Share

COinS